Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2006 4
2007 5
2008 1
2009 1
2012 1
2013 2
2014 1
2017 3
2018 2
2019 6
2020 6
2021 6
2022 6
2023 9
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

55 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Aldoss I, Yang D, Aribi A, Ali H, Sandhu K, Al Malki MM, Mei M, Salhotra A, Khaled S, Nakamura R, Snyder D, O'Donnell M, Stein AS, Forman SJ, Marcucci G, Pullarkat V. Aldoss I, et al. Among authors: aribi a. Haematologica. 2018 Sep;103(9):e404-e407. doi: 10.3324/haematol.2018.188094. Epub 2018 Mar 15. Haematologica. 2018. PMID: 29545346 Free PMC article. No abstract available.
HIV-1 Remission after Allogeneic Hematopoietic-Cell Transplantation.
Dickter JK, Aribi A, Cardoso AA, Gianella S, Gendzekhadze K, Li S, Feng Y, Chaillon A, Laird GM, Browning DL, Ross JA, Nanayakkara DD, Puing A, Stan R, Lai LL, Chang S, Kidambi TD, Thomas S, Al Malki MM, Nakamura R, Alvarnas J, Taplitz RA, Dadwal SS, Forman SJ, Zaia JA. Dickter JK, et al. Among authors: aribi a. N Engl J Med. 2024 Feb 15;390(7):669-671. doi: 10.1056/NEJMc2312556. N Engl J Med. 2024. PMID: 38354149 No abstract available.
Favorable Activity and Safety Profile of Memory-Enriched CD19-Targeted Chimeric Antigen Receptor T-Cell Therapy in Adults with High-Risk Relapsed/Refractory ALL.
Aldoss I, Khaled SK, Wang X, Palmer J, Wang Y, Wagner JR, Clark MC, Simpson J, Paul J, Vyas V, Chien SH, Stein A, Pullarkat V, Salhotra A, Al Malki MM, Aribi A, Sandhu K, Thomas SH, Budde LE, Marcucci G, Brown CE, Forman SJ. Aldoss I, et al. Among authors: aribi a. Clin Cancer Res. 2023 Feb 16;29(4):742-753. doi: 10.1158/1078-0432.CCR-22-2038. Clin Cancer Res. 2023. PMID: 36255386 Free PMC article.
WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.
Aribi A, Salhotra A, Afkhami M, Munteanu A, Ali H, Aldoss I, Otoukesh S, Al Malki MM, Sandhu KS, Koller P, Arslan S, Stewart F, Artz A, Curtin P, Ball B, O'Hearn J, Spielberger R, Smith E, Budde E, Nakamura R, Stein A, Forman S, Marcucci G, Becker PS, Pullarkat V. Aribi A, et al. Leuk Lymphoma. 2023 Nov-Dec;64(11):1811-1821. doi: 10.1080/10428194.2023.2241096. Epub 2023 Aug 3. Leuk Lymphoma. 2023. PMID: 37533373
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
Ong SY, Pak S, Mei M, Wang Y, Popplewell L, Baird JH, Herrera AF, Shouse G, Nikolaenko L, Zain J, Godfrey J, Htut M, Aribi A, Spielberger R, Mansour J, Forman SJ, Palmer J, Budde LE. Ong SY, et al. Among authors: aribi a. Am J Hematol. 2023 Nov;98(11):1751-1761. doi: 10.1002/ajh.27069. Epub 2023 Sep 5. Am J Hematol. 2023. PMID: 37668287
High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions.
Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, Pourhassan H, Agrawal V, Koller P, Arslan S, Tomasian V, Al Malki MM, Artz A, Salhotra A, Ali H, Aribi A, Sandhu KS, Ball B, Otoukesh S, Amanam I, Becker PS, Stewart FM, Curtin P, Smith E, Telatar M, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. Aldoss I, et al. Among authors: aribi a. Am J Hematol. 2023 Jun;98(6):848-856. doi: 10.1002/ajh.26908. Epub 2023 Mar 16. Am J Hematol. 2023. PMID: 36880203 Free article.
Novel approaches in the treatment of systemic mastocytosis.
Quintas-Cardama A, Aribi A, Cortes J, Giles FJ, Kantarjian H, Verstovsek S. Quintas-Cardama A, et al. Among authors: aribi a. Cancer. 2006 Oct 1;107(7):1429-39. doi: 10.1002/cncr.22187. Cancer. 2006. PMID: 16948123 Free article. Review.
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
Ngo D, Tinajero J, Li S, Palmer J, Pourhassan H, Aribi A, Nakamura R, Stein A, Marcucci G, Salhotra A, Sandhu K, Pullarkat V, Ball B, Koller P. Ngo D, et al. Among authors: aribi a. Leuk Lymphoma. 2024 Mar;65(3):372-377. doi: 10.1080/10428194.2023.2292473. Epub 2024 Jan 2. Leuk Lymphoma. 2024. PMID: 38164785
Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab.
Agrawal V, Pourhassan H, Tsai NC, Ngo D, Koller P, Malki MMA, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Ball B, Otoukesh S, Amanam I, Artz A, Singh D, Becker PS, Stewart FM, Smith EP, Curtin P, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V, Aldoss I. Agrawal V, et al. Among authors: aribi a. Transplant Cell Ther. 2023 May;29(5):314-320. doi: 10.1016/j.jtct.2023.01.017. Epub 2023 Jan 19. Transplant Cell Ther. 2023. PMID: 36682470 Free article.
Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide.
Al Malki MM, Palmer J, Tsai NC, Mokhtari S, Hui S, Tsai W, Aldoss I, Ali H, Aribi A, Cao T, Mei M, Sandhu KS, Siddiqi T, Forman SJ, Nakamura R, Marcucci G, Stein A, Wong JYC, Rosenthal J. Al Malki MM, et al. Among authors: aribi a. Blood Adv. 2022 Jul 26;6(14):4098-4106. doi: 10.1182/bloodadvances.2022007264. Blood Adv. 2022. PMID: 35838754 Free PMC article. Clinical Trial.
55 results